Leadership

Sherry Shao

Ms. Sherry Shao currently serves as rotating chief executive officer of the Company. She was appointed as the chief operating officer of the Company on July 8, 2021 and is primarily responsible for the supporting functions of the Company, including human resources, supply chain, engineering and instrument, information technology, quality and environmental, health and safety functions. She is also a member of the sanctions risk control committee.

Ms. Shao has over 17 years of management experience in the life-science and biologics development industry. Ms. Shao joined the Group in July 2005. From July 2005 to April 2017, Ms. Shao served in a number of positions at the Group, including a group leader of antibody department, a manager of antibody development and a vice president of reagent service production center. From April 2017 to April 2019, Ms. Shao worked as the deputy general manager of the reagent service business unit. From April 2019 to August 2020, Ms. Shao served as the president of life science group. From August 2020 to February 2021, she worked as the president of European division. From February 2021 to July 2021, she worked as China President. She was appointed as the chief operating officer of the Company in July 2021.

Ms. Shao, obtained her Bachelor of Science degree in biology from Nanjing Normal University in the PRC in June 2002 and a Master of Science degree in Preventive Veterinary from Yangzhou University in the PRC in June 2005.

Dr. Patrick Liu

Dr. Patrick Liu currently serves as a rotating chief executive officer of the Company. He has been appointed as chief executive officer of the Company, subject to retirement by rotation on yearly basis, with effect from August 2, 2020 and is primarily responsible for overseeing the Company’s daily operations. He completed his term of duty on December 31, 2022 and will remain as a rotating chief executive officer of the Company. He sits on the Board of Directors of ProBio.

Dr. Liu has over 13 years of management experience in the life-science and biologics development industry. Dr. Liu joined the Group in May 2009. From May 2009 to August 2015, Dr. Liu served in a number of positions at the Group, including as a senior scientist of discover biology, a director of bioprocess development and a director of institute of biotechnology research. From September 2015 to April 2019, Dr. Liu worked as the general manager of the reagent service business unit. From January 2017 to April 2019, Dr. Liu served as the president of biosciences group. From April 2019 to August 2020, he worked as the president of European division of the Company. He was appointed as the rotating chief executive officer of the Company in August 2020. Dr. Liu is currently a director of CustomArray Inc. and the chairman of the board of directors of Probio Technology Limited. Prior to joining the Group, Dr. Liu was a postdoctoral scholar at David Geffen School of Medicine of University of California, Los Angeles from November 2007 to May 2009.

Dr. Liu holds a Bachelor in Science degree in biochemistry and molecular biology from Nankai University in the PRC in June 1998, a Master in Science degree in neurophysiology from Peking University in the PRC in June 2001 and a Doctor of Philosophy degree in neurobiology from University of Pittsburgh School of Medicine in the U.S. in November 2007.

Shiniu Wei

Mr. Shiniu Wei has served as the Chief Financial Officer of the Company since December 1, 2020, and is primarily responsible for the Company’s overall financial operations management. Mr. Wei joined the Group in September 2019 as vice president of strategy and investor relations.

Prior to joining the Group, Mr. Wei worked as an executive director of secondary market investment department in Fosun Insurance Group in New York from 2017 to 2019. He served as an equity investment analyst and a portfolio manager in Investment Strategies Fund from 2010 to September 2016. From 2009 to May 2010, he worked as an analyst at Protocol Capital Management and prior to that, he worked as a researcher of Research Foundation at the City University of New York.

Mr. Wei obtained his Bachelor of Science degree in Biochemistry from Nanjing University in 2000 and his Master degree in Business Administration from Baruch College in 2011.

Dr. Ying Huang

Dr. Ying Huang currently serves as the Chief Executive Officer of Legend Biotech, a cell therapy subsidiary of GenScript Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics.

Dr. Huang brings over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch where he led a team of analysts covering more than 30 biotechnology companies that encompass a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top ranked biotechnology analyst on Wall Street. Dr. Huang previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer reviewed publications.

Dr. Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.

Dr. Ray Chen

Dr. Ray Chen has been with GenScript since 2012 and is the President of GenScript Life Science Group. He held positions at GenScript of increasing responsibilities including Sales and Technical support, Business development, Product development and Marketing, R&D and production operations. Currently, he leads GenScript Life Science group’s global commercial teams, R&D centers and manufacturing sites in China, Singapore and United States to provide reliable, high quality and innovative reagent products, custom services and instrument serving a wide variety of existing and emerging life science research and development areas. Before joining GenScript, he held positions in Fabric and Home care R&D at Proctor & Gamble in product design and development.

Dr. Chen studied peptide chemistry in Dr. Richard DiMarchi lab and earned his PhD in Chemistry from Indiana University Bloomington and BS in Chemistry from Nanjing University.

Dr. Li Chen

Dr. Li Chen is CEO of Probio, a biologics CDMO subsidiary of GenScript Biotech.

Before she joined GenScript in 2023, she served as Vice President/General Manager of Biologics at West Pharmaceutical Services, with extensive experience in strategic business planning, excellent operations, and cultivating strong businesses in different biotechnology fields. From 2011 to 2021，she worked at Thermo Fisher Scientific for 10 years, successfully led a strategic transformation to a direct business model and implemented a new marketing model, enhancing business performance in the Asia Pacific region, including Japan. From 2005 to 2011, she first joined Sigma Aldrich as the Sales and Marketing Director，and gradually held important leadership positions in companies such as Millipore and Merck.

Dr. Li Chen holds a Bachelor of Biochemistry of Nanjing University, Doctor of Molecular Biology and Biochemistry of Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and later engaged in postdoctoral research at Yale University and University of California, Berkeley Executive MBA of China Europe International Business School.

Dr. Aixi Bai

Dr. Bai is the General Manager of Bestzyme, a Industrial synthetic biology products subsidiary of GenScript Biotech. Dr. Bai oversees comprehensive management duties, including production, research and development, business operations activities. Before he became the General Manager of Bestzyme in 2022, Dr. Bai was the Head of R&D at Bestzyme in 2018, where he was responsible for managing daily R&D operations. He joined Bestzyme in 2013 as a Senior Researcher, focusing on enzyme preparation project development.

Dr. Bai specializes in enzyme molecular discovery and enzyme engineering. He has 12 granted patents and patent applications, as well as 7 publications in peer-reviewed journals. Dr. Bai obtained his Bachelor's degree in Biological Sciences from Jilin University in 2005 and his Ph.D. in Microbiology from the same institution in 2012.

Ernest Lee

Mr. Ernest Lee currently serves as the head of Sustainability at GenScript. During his tenure at GenScript, he has successfully reduced regulated medical waste disposal volume and cost, while increasing capacity and reducing costs at the GenScript US site. He developed supply chain simulation models to minimize costs and optimize the inventory management process. Lee also mentored engineers on data-driven decision-making.

Mr. Ernest Lee previously worked at Johnson & Johnson, Merck, Medarex, Kaverner Engineering, and Atlantic Richfield. During his tenure at Johnson & Johnson, he earned two Achievement Awards for his work on Liquid Suspension High Shear Manufacturing Technology and the design of Lactase Enzyme Production Facilities. He also applied chemical separation sciences and designed experiments to prevent a costly FDA national product recall. At Merck, Ernest was selected as the Team Champion for the Pharmaceutical Maximum Achievable Control Technology (MACT) Environmental Project. He served as the Field Engineering Lead for Resource Conservation and Recovery Act (RCRA) Environmental Projects, focusing on a revamped organic synthesis facility. Additionally, he analyzed and designed critical components for novel gelatin coating machines, which were essential for a nationwide pharmaceutical product launch. Ernest also developed dynamic and stochastic models for facility systems and operations.

Ernest holds a Bachelor of Science in Mechanical Engineering from Cornell University, as well as a Master of Science in Industrial Engineering and a Master of Science in Engineering Management, both from the New Jersey Institute of Technology.

Dr. Raymond Miller

Dr. Raymond Miller is the Head of Corporate Communications. With over 12 years of experience in cross-functional communication, market research, strategy, and product development, Raymond has successfully led multiple global product management teams at GenScript. His notable achievements include building internal communication and information-sharing channels, establishing market intelligence programs, and launching nine nucleic acid reagent services.

Before joining GenScript, Raymond held various commercial and product management roles at Agilent Technologies and Bio-Rad Laboratories, where he took on increasing responsibilities. Key highlights from his tenure at these organizations include developing the SureSelect™ XT HS2 RNA Reagent Kit and globally launching the ChemiDoc™ MP Imaging system.

Dr. Raymond holds a PhD in Biochemistry and Molecular Biology from Virginia Tech.

Bhama Parimoo

Dr. Bhama Parimoo now serves as the Head of Global DEI. At GenScript, she has been instrumental in implementing the customer relationship platform and has contributed significantly to technical, sales, and business development efforts. In the Quality Assurance department, she addressed and resolved challenging issues, promoting our products and services to clients globally while receiving notable recognition. Her dedication and achievements have made her a three-time winner of the Best Employee of the Year award, in addition to receiving service awards.

After completing a postdoctoral fellowship at the University of Southern California School of Medicine, she worked as an Associate Research Scientist at the Yale School of Medicine and later served as a junior faculty member at Rutgers University before joining GenScript. She has published her work in peer-reviewed journals and presented at several conferences both in the US and internationally. Bhama holds a Ph.D. in Biochemistry and Molecular Biology from a prestigious research institute in India.